You are here

praluzatamab ravtansine

CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt

Fierce Biotech

Thu, 07/14/22 - 10:58 am

CytomX Therapeutics

praluzatamab ravtansine

CytomX halts lead program and will seek a partner as breast cancer drug disappoints

Endpoints

Thu, 07/7/22 - 10:26 am

clinical trials

praluzatamab ravtansine